The clinical safety of ibrutinib in chronic lymphocytic leukemia

Expert Opinion on Drug Safety

Volumn 14, Issue 10, 2015, Pages 1621-1629

  Molica, Stefano ^a  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

chronic lymphocytic leukemia; clinical use; ibrutinib; ibrutinib association; management toxicities; safety; toxicities

Indexed keywords

BENDAMUSTINE; IBRUTINIB; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LEUKEMIA RELAPSE; LYMPHOCYTOSIS; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; PYRAZOLES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942296966     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1084286     Document Type: Article

References (57)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9-29
2. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012; 122 (10): 3432-8
3. Stilgenbauer S, Furman RR, Zent CS. Management of chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book 2015; 35: 164-75
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376 (9747): 1164-74
5. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) shows superior efficacy in comparison to bendamustine and rituximab (BR) in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract 19]. American Society of Hematology (ASH) Annual Meeting; 6-9 December 2014; San Francisco, CA
6. Cuneo A, Marchetti M, Barosi G, et al. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leuk Res 2014; 38 (11): 1269-77
7. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-10
8. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015; 385 (9980): 1873-83
9. Robak T. Maintenance in CLL. Blood 2013; 122 (24): 3854-5
10. Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the international randomized AGMT-CLL8/a Mabtenance trial [abstract 20]. American Society of Hematology (ASH) Annual Meeting; 6-9 December 2014; San Francisco, CA
11. van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis result [abstract 21]. American Society of Hematology (ASH) Annual Meeting; 6-9 December 2014; San Francisco, CA
12. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011; 118 (19): 5126-9
13. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111 (11): 5291-7
14. James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 2014; 32 (19): 2067-73
15. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol 2015; 90 (5): 446-60
16. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369 (1): 32-42
17. Byrd JC, Brown JR, OBrien S, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371 (3): 213-23
18. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370 (11): 997-1007
19. Davids MS, Pagel JM, Kahl BS, et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 2013; 122 (21): 872-7
20. Bruton OC, Apt L, Gitlin D, et al. Absence of serum gamma globulins. AMA American Journal of Diseases of Children 1952; 84: 632-6
21. Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Brutons tyrosine kinase in immunodeficient XID mice. Science 1993; 261: 358-61
22. Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia 1993. J Immunol 2012; 188: 2936-47
23. Rickert R. New insights into pre-BCR and BCR signalling with relevance to C cell malignancies. Nature 2013; 13 (8): 578-91
24. Choi M, Kipps T. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 2013; 18 (5): 404-10
25. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 2010; 14 (4): 475-80
26. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107 (29): 13075-80
27. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122 (15): 2539-49
28. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31 (1): 88-94
29. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369 (6): 507-16
30. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111 (12): 5446-56
31. OBrien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014; 15 (1): 48-58
32. A Multicenter, Open-label, Phase 3 Study of the Brutons Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2). Available from: https://clinicaltrials.gov/ct2/show/NCT01722487
33. Barrientos JC, OBrien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract 4696]. American Society of Hematology (ASH) Annual Meeting; 6-9 December 2014; San Francisco, CA
34. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15 (10): 1090-9
35. Brown JR, Barrientos JC, Barr PM, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015; 125 (19): 2915-22
36. Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol 2015; 11 (1): 51-9
37. Chanan-Khan A, Cramer P, Dermirkan F, et al. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. J Clin Oncol 2015; 33 (Suppl): abstr LBA7005
38. Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02048813
39. A multi-center study of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab in patients with treatment naïve CLL or SLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02264574
40. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Brutons tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370 (24): 2286-94
41. Maddocks KM, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol 2015; 1 (1): 80-7
42. Barr PM, Brown JR, Hillmen P, et al. Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated CLL. J Clin Oncol 2015; 33: suppl; abstr 7012
43. Rossi D, Gaidano G. Lymphocytosis and ibrutinib treatment of CLL. Blood 2014; 123 (12): 1772-4
44. Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28 (11): 2188-96
45. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014; 123 (12): 1810-17
46. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30 (23): 2820-2
47. Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011; 96 (5): 752-61
48. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-80
49. Montillo M, OBrien S, Tedeschi A, et al. Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. Proceedings of 56th ASH Annual Meeting and Exposition, 6-9 December 2014, San Francisco, CA, abstr 5654
50. Rogers KA, Woyach JA, Andritsos LA, et al. Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib. Proceedings of 56th ASH Annual Meeting and Exposition, 6-9 December 2014, San Francisco, CA, abstr. 1997
51. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014; 124 (26): 3991-5
52. Jones JA, Hillmen P, Coutre S, et al. Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Proceedings of 56th ASH Annual Meeting and Exposition, 6-9 December 2014, San Francisco, CA, abstr. 1990
53. Treon SP, Palomba L, Tripsas C, et al. Ibrutinib in previously treated patients with Waldenstroms macroglobulinemia [abstract]. In: Proceedings of the 8th International Workshop on Waldenstroms Macroglobulinemia; 13-17 August 2014; London, UK, Abstract X.5
54. McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124 (25): 3829-30
55. Thompsonm PA, Wierda WG, Ferrajoli A, et al. Complex karyotype, rather than del (17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens. Cancer 2015. [Epub ahead of print]
56. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agentibrutinib. Blood 2015; 125 (16): 2497-506
57. Forconi F. Three years of ibrutinib in CLL. Blood 2015; 125 (16): 2455-6